BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines Academic Article uri icon

Overview

MeSH Major

  • Carcinoma
  • Drug Resistance, Neoplasm
  • Mitogen-Activated Protein Kinase Kinases
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf
  • Thyroid Neoplasms

abstract

  • Thyroid cancers with BRAF mutation are preferentially sensitive to MEK inhibitors, whereas tumors with other MEK-ERK effector pathway gene mutations have variable responses, either because they are only partially dependent on ERK and/or because feedback responses elicit partial refractoriness to MEK inhibition.

publication date

  • June 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2435640

Digital Object Identifier (DOI)

  • 10.1210/jc.2007-2825

PubMed ID

  • 18381570

Additional Document Info

start page

  • 2194

end page

  • 201

volume

  • 93

number

  • 6